Tenet Healthcare Corporation

NYSE:THC Stock Report

Market Cap: US$17.5b

Tenet Healthcare Valuation

Is THC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of THC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: THC ($203.72) is trading below our estimate of future cash flow value ($491.56)

Significantly Below Future Cash Flow Value: THC is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for THC?

Key metric: As THC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for THC. This is calculated by dividing THC's market cap by their current earnings.
What is THC's PE Ratio?
PE Ratio10.3x
EarningsUS$1.70b
Market CapUS$17.55b

Price to Earnings Ratio vs Peers

How does THC's PE Ratio compare to its peers?

The above table shows the PE ratio for THC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20x
EHC Encompass Health
17.8x9.61%US$10.6b
UHS Universal Health Services
6.3x-0.29%US$9.6b
ENSG Ensign Group
26.8x13.21%US$9.7b
PACS PACS Group
28.9x16.65%US$7.0b
THC Tenet Healthcare
10.3x-8.95%US$17.5b

Price-To-Earnings vs Peers: THC is good value based on its Price-To-Earnings Ratio (10.3x) compared to the peer average (20x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does THC's PE Ratio compare vs other companies in the US Healthcare Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CYH Community Health Systems
1.1x-109.55%US$528.27m
IDXG Interpace Biosciences
1.9xn/aUS$45.15m
NIVF NewGenIvf Group
0.5xn/aUS$4.75m
RHEP Regional Health Properties
1.1xn/aUS$4.13m
THC 10.3xIndustry Avg. 25.9xNo. of Companies11PE020406080100+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: THC is good value based on its Price-To-Earnings Ratio (10.3x) compared to the US Healthcare industry average (25.9x).

Price to Earnings Ratio vs Fair Ratio

What is THC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

THC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.3x
Fair PE Ratio19x

Price-To-Earnings vs Fair Ratio: THC is good value based on its Price-To-Earnings Ratio (10.3x) compared to the estimated Fair Price-To-Earnings Ratio (19x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst THC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$203.72
US$243.19
+19.37%
8.45%US$288.00US$210.00n/a21
Jun ’27US$170.09
US$244.57
+43.79%
7.88%US$288.00US$210.00n/a21
May ’27US$183.27
US$253.38
+38.26%
7.19%US$288.00US$213.00n/a21
Apr ’27US$190.27
US$261.38
+37.37%
6.30%US$288.00US$213.00n/a21
Mar ’27US$239.39
US$257.00
+7.36%
6.71%US$288.00US$213.00n/a21
Feb ’27US$189.28
US$237.67
+25.56%
8.26%US$270.00US$172.00n/a21
Jan ’27US$198.72
US$237.24
+19.38%
7.83%US$260.00US$172.00n/a21
Dec ’26US$215.13
US$233.43
+8.51%
9.73%US$260.00US$167.00n/a21
Nov ’26US$206.49
US$229.62
+11.20%
10.14%US$260.00US$167.00n/a21
Oct ’26US$201.34
US$201.43
+0.044%
10.17%US$238.00US$160.00n/a21
Sep ’26US$184.33
US$197.52
+7.16%
8.95%US$238.00US$160.00n/a21
Aug ’26US$158.09
US$196.81
+24.49%
9.01%US$238.00US$160.00n/a21
Jul ’26US$177.43
US$186.83
+5.30%
9.88%US$230.00US$154.00US$191.2022
Jun ’26US$168.77
US$179.92
+6.61%
9.90%US$230.00US$144.21US$170.0922
May ’26US$145.29
US$171.87
+18.30%
12.03%US$230.00US$134.00US$183.2722
Apr ’26US$133.40
US$171.37
+28.47%
10.59%US$217.00US$134.00US$190.2722
Mar ’26US$126.59
US$172.30
+36.10%
10.85%US$217.00US$134.00US$239.3921
Feb ’26US$140.89
US$177.21
+25.78%
10.70%US$217.00US$140.00US$189.2820
Jan ’26US$126.23
US$179.46
+42.17%
11.26%US$217.00US$140.00US$198.7220
Dec ’25US$142.68
US$182.46
+27.88%
10.28%US$217.00US$140.00US$215.1320
Nov ’25US$156.13
US$182.80
+17.08%
9.52%US$217.00US$140.00US$206.4920
Oct ’25US$162.87
US$172.35
+5.82%
8.55%US$197.00US$128.00US$201.3420
Sep ’25US$165.84
US$171.35
+3.32%
8.06%US$197.00US$128.00US$184.3320
Aug ’25US$147.95
US$166.43
+12.49%
8.78%US$190.00US$128.00US$158.0920
Jul ’25US$133.30
US$141.93
+6.47%
11.09%US$165.00US$104.00US$177.4320
US$243.19
Fair Value
16.2% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 06:09
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tenet Healthcare Corporation is covered by 32 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hua HaBaird
Adam FeinsteinBarclays
Andrew MokBarclays